Related Experiment Video

Updated: Jul 18, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Application of 18F-PSMA-1007 PET/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a

Małgorzata Mojsak1, Piotr Szumowski2, Anna Amelian1

  • 1Independent Laboratory of Molecular Imaging, Medical University of Bialystok, 15-276 Bialystok, Poland.

Cancers
|August 26, 2023
PubMed

Insights

18F-PSMA-1007 PET/MR effectively detects early biochemical recurrence (BCR) in prostate cancer patients with low PSA levels. This imaging technique shows promise for identifying recurrence, particularly when PSA is below 0.5 ng/mL.

Area of Science:

  • Nuclear medicine imaging
  • Prostate cancer diagnostics
  • Radiopharmaceutical applications

Background:

  • 18F-PSMA-1007 PET/MR is emerging for prostate cancer diagnosis.
  • Its role in detecting early biochemical recurrence (BCR) is under investigation.
  • Current European Association of Urology (EAU) guidelines do not yet include this technique.

Purpose of the Study:

  • To evaluate the diagnostic performance of 18F-PSMA-1007 PET/MR in identifying BCR lesions.
  • To assess effectiveness at very low prostate-specific antigen (PSA) levels (<0.5 ng/mL).

Main Methods:

  • Prospective study of 60 patients with BCR post-radical prostatectomy.
  • Patients had PSA levels between 0.1-0.5 ng/mL.
  • Simultaneous whole-body and pelvic 18F-PSMA-1007 PET/MR was performed, with 12-month follow-up for verification.

Main Results:

  • A 75% detection rate, identifying 53 lesions in 45 patients.
  • Mean PSA level was 0.31 ng/mL.
  • Lesions were predominantly pelvic (91%), with local recurrences (29%), PSMA-positive lymph nodes (64%), and bone metastases (7%).

Conclusions:

  • 18F-PSMA-1007 PET/MR is a valuable tool for early BCR detection in prostate cancer.
  • The technique is particularly effective at very low PSA levels (<0.5 ng/mL) and with a PSA doubling time (dt PSA) < 6 months.
  • Combining 18F-PSMA-1007 with whole-body PET/MR offers precise assessment for early BCR management.
Keywords:
18F-PSMA-1007PET/MRprostate cancer

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

278
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.3K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
154